Boston Scientific Files 8-K for Senior Notes
Ticker: BSX · Form: 8-K · Filed: Nov 15, 2024 · CIK: 885725
| Field | Detail |
|---|---|
| Company | Boston Scientific CORP (BSX) |
| Form Type | 8-K |
| Filed Date | Nov 15, 2024 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.01, $71, $3.7 billion, $3.3 billion |
| Sentiment | neutral |
Sentiment: neutral
Topics: debt-issuance, financing
Related Tickers: BSX
TL;DR
BSX is issuing new debt, filing 8-K for notes due 2027.
AI Summary
Boston Scientific Corporation (BSX) announced on November 15, 2024, that it has entered into an agreement for senior notes due in 2027. The filing does not disclose specific financial details or the exact purpose of these notes, but it is a standard disclosure for debt issuance.
Why It Matters
This filing indicates Boston Scientific is raising capital through debt, which could be for general corporate purposes, acquisitions, or refinancing existing debt.
Risk Assessment
Risk Level: low — This is a routine debt issuance filing with no immediate negative or positive financial implications disclosed.
Key Players & Entities
- Boston Scientific Corporation (company) — Registrant
- BSX (company) — Ticker Symbol
- November 15, 2024 (date) — Report Date
- 2027 (date) — Maturity Year of Senior Notes
FAQ
What is the principal amount of the senior notes due 2027?
The filing does not specify the principal amount of the senior notes due 2027.
What is the interest rate on the senior notes due 2027?
The filing does not disclose the interest rate for the senior notes due 2027.
What is the intended use of the proceeds from the senior notes due 2027?
The filing does not detail the specific use of proceeds for the senior notes due 2027.
When was the agreement for the senior notes due 2027 finalized?
The filing indicates the report date is November 15, 2024, suggesting the agreement was likely finalized around this date.
Are there any specific covenants or conditions associated with these senior notes?
The filing does not provide details on specific covenants or conditions for the senior notes due 2027.
Filing Stats: 1,272 words · 5 min read · ~4 pages · Grade level 16.5 · Accepted 2024-11-15 16:02:24
Key Financial Figures
- $0.01 — ange on which registered Common Stock, $0.01 par value per share BSX New York Stock
- $71 — owel dysfunction. The purchase price of $71 cash per share represents an equity val
- $3.7 billion — per share represents an equity value of $3.7 billion and an enterprise value of $3.3 billion
- $3.3 billion — $3.7 billion and an enterprise value of $3.3 billion net of cash and short-term investments
Filing Documents
- bsx-20241115.htm (8-K) — 34KB
- ex991pressrelease-axonicsc.htm (EX-99.1) — 14KB
- image_0.jpg (GRAPHIC) — 57KB
- 0000885725-24-000078.txt ( ) — 293KB
- bsx-20241115.xsd (EX-101.SCH) — 3KB
- bsx-20241115_def.xml (EX-101.DEF) — 15KB
- bsx-20241115_lab.xml (EX-101.LAB) — 27KB
- bsx-20241115_pre.xml (EX-101.PRE) — 16KB
- bsx-20241115_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On November 15, 2024, Boston Scientific Corporation (the "Company") completed its acquisition of Axonics, Inc. ("Axonics"), a public medical technology company focused on the development and commercialization of differentiated devices to treat urinary and bowel dysfunction. The purchase price of $71 cash per share represents an equity value of $3.7 billion and an enterprise value of $3.3 billion net of cash and short-term investments acquired. The transaction is expected to be immaterial to adjusted earnings per share in 2024 and 2025 and accretive thereafter. On a GAAP basis, the transaction is expected to be less accretive, or more dilutive, due to amortization expense and acquisition-related charges. A copy of the Company's press release announcing the completion of the acquisition of Axonics is included as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference; provided, however, that information on or connected to our website or the website of any third-party hyperlinked from or referenced in the Company's press release included as Exhibit 99.1 to this Current Report on Form 8-K is expressly not incorporated by reference into or intended to be filed as a part of this Current Report on Form 8-K. Cautionary Statement Regarding Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding the financial and business impact of
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release issued by Boston Scientific Corporation, dated November 1 5, 2 02 4 104 Cover Page Interactive Date File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 15, 2024 BOSTON SCIENTIFIC CORPORATION By: /s/ Susan Thompson Susan Thompson Vice President, Chief Corporate Counsel and Assistant Secretary